Whereas the disease was once thought to affect only adults, it now appears that most infections are acquired in childhood. Initial infection is followed by a long period of subclinical disease, which progresses in later life to clinically manifest disease. Lymphatic filariasis can cause of variety of clinical manifestations, that can be grouped in three categories: acute attacks, lymphoedema/elephantiasis and hydrocoele.

Lymphatic filariasis, commonly known as elephantiasis, is a painful and profoundly disfiguring disease. It is caused by infection with parasites classified as nematodes (roundworms) of the family Filariodidea that are transmitted through the bites of infected mosquitos. Mosquito-transmitted larvae are deposited on the skin from where they can enter the body. The larvae then migrate to the lymphatic vessels where they develop into adult worms, thus continuing a cycle of transmission.

Leprosy is curable with a combination of drugs known as multidrug therapy, as the treatment of leprosy with only one antileprosy drug (monotherapy) will result in development of drug resistance to that drug. The combination of drugs used in the MDT depends on the classification of the disease (paucibacillary or multibacillary leprosy

Leprosy, also known as Hansen’s disease, is a chronic infectious disease caused by Mycobacterium leprae. The disease mainly affects the skin, the peripheral nerves, mucosal surfaces of the upper respiratory tract and the eyes. Leprosy is known to occur at all ages ranging from early infancy to very old age. Leprosy is curable and treatment in the early stages can prevent disability.

Leprosy is likely transmitted via droplets, from the nose and mouth, during close and frequent contact with untreated cases

Antileishmanial treatment depends on the causative species and the condition of the patient (e.g. pregnancy, immunosuppression).

Regardless of the causative Leishmania species, antileishmanial treatment cannot provide a sterile cure, and the parasite remains in the human body and can cause a relapse when there is immunosuppression.

Treatment is complex and should be administered by highly experienced health personnel. Most antileishmanial medicines are injectable